Sunday 11 October 2026 Export all LLY data to Excel Powerpack

Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.

1,179.27 9.67 +0.83%
Market cap
$1.10T
P/E
39.6×
Fwd P/E
33.1×
Dividend yield
0.57%
F-score
7/9
Altman Z
8.61
Beneish M
−1.91
Dividend safety
86/100
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
46.83 65.93 102.10 52.90 44.99 24.83 14.97 36.97 0.00 28.91
Piotroski F-Score
7 6 5 7 6 6 6 9 4 6
Altman Z-Score
8.61 7.89 6.99 6.47 5.14 3.57 3.23 3.52 2.75 3.42
P/S ratio
14.79 15.44 15.62 11.53 8.85 6.24 5.48 5.53 4.46 3.72
P/FCF ratio
86.31 116.64 216.52 56.77 38.74 27.75 29.05 25.18 18.00 18.37
Altman Z″-Score (non-manufacturers)
3.79 2.26 1.26 2.04 2.17 2.27 1.66 3.03 2.35 3.21
Beneish M-Score
(1.91) (2.21) (2.18) (2.58) (2.47) (2.26) (2.52) (2.64) (3.04) (2.62)
P/Operating CF
299.05 281.04 (1,708.65) 197.95 110.77 84.42 62.32 82.09 51.10 39.35
Dividend Safety Score
86 — — — — — — — — —
P/B ratio
36.34 48.72 49.07 30.54 27.37 26.31 45.34 10.90 7.64 5.61
Price to Tangible BV
68.31 297.63 0.00 0.00 0.00 0.00 0.00 14.03 27.25 13.73
EV/Sales
15.34 16.02 16.14 12.02 9.30 6.77 6.07 5.62 4.56 3.83
EV/EBITDA
35.32 49.20 68.98 39.67 33.33 22.51 21.81 23.47 25.49 17.09
EV/Operating CF
59.45 81.84 129.89 45.24 35.77 25.56 27.99 21.85 16.21 16.76
EV/FCF
89.46 121.06 223.69 59.19 40.75 30.09 32.13 25.56 18.39 18.92
Quick Ratio
0.78 0.58 0.52 0.63 0.80 0.85 0.68 1.11 0.91 0.98
Current Ratio
1.58 1.15 0.94 1.05 1.23 1.40 1.16 1.73 1.32 1.37
Net Debt/EBITDA
1.19 1.72 1.93 1.45 1.45 1.75 2.09 0.56 1.57 0.90
Debt/Assets
36.33% 36.24% 28.62% 29.78% 31.44% 35.59% 39.30% 23.45% 30.34% 26.55%
Debt/Equity
1.54 2.00 1.69 1.37 1.68 2.85 5.72 0.94 1.17 0.73
Asset Turnover
0.68 0.63 0.60 0.58 0.59 0.57 0.54 0.48 0.48 0.57
Operating CF/Net income
0.81 0.83 0.81 1.21 1.32 1.05 0.58 1.71 (27.51) 1.77
Capex/Depreciation
(3.93) (2.86) (2.26) (1.22) (0.85) (1.05) (0.84) (0.75) (0.69) (0.64)
ROE
101.16% 84.26% 48.43% 62.67% 74.52% 145.32% 122.26% 28.63% (1.59%) 19.10%
ROA
21.59% 14.84% 9.23% 12.71% 11.70% 14.42% 20.00% 7.27% (0.49%) 7.36%
ROIC
27.34% 20.39% 15.37% 19.12% 19.29% 20.20% 19.80% 16.01% 7.25% 11.11%
Return on Tangible Assets
45.79% 49.33% 46.18% 56.56% 45.07% 45.33% 84.82% 19.40% (1.51%) 22.14%
Average Days of Receivables
112.87 107.58 121.26 109.46 104.75 103.06 90.62 98.10 96.16 81.98
Research and Development Expense of Revenue
20.46% 24.40% 27.29% 25.19% 24.47% 24.35% 25.07% 23.50% 25.51% 25.02%
Selling, General and Administrative Expense of Revenue
17.02% 19.08% 21.70% 22.57% 22.71% 24.94% 27.84% 27.80% 29.95% 30.76%
Intangible Assets out of Total Assets
0.11 0.15 0.19 0.23 0.24 0.24 0.26 0.06 0.19 0.21
Share Based Compensation of Revenue
0.96% 1.43% 1.84% 1.30% 1.21% 1.26% 1.40% 1.30% 1.41% 1.20%
Graham Net Nets
(0.03) (0.05) (0.05) (0.06) (0.08) (0.15) (0.19) (0.10) (0.16) (0.12)
Graham Number
123.57 64.62 39.68 43.07 37.34 31.34 23.93 27.34 0.00 27.79
Earnings Yield
2.14% 1.52% 0.98% 1.89% 2.22% 4.03% 6.68% 2.70% (0.24%) 3.46%
Free Cash Flow Yield
1.16% 0.86% 0.46% 1.76% 2.58% 3.60% 3.44% 3.97% 5.56% 5.44%
Revenue per Share
72.64 50.01 37.91 31.65 31.22 27.04 23.97 20.91 18.99 20.05
Operating CF per Share
18.74 9.79 4.71 8.41 8.12 7.16 5.19 5.38 5.34 4.58
Capex per Share
(8.74) (5.62) (3.83) (2.06) (1.44) (1.53) (1.11) (1.18) (1.02) (0.91)
Free Cash Flow per Share
10.00 4.18 0.88 6.36 6.68 5.63 4.08 4.20 4.31 3.67
Cash per Share
8.10 3.63 3.25 2.45 4.31 4.06 2.62 7.21 7.64 5.71
Shareholders Equity per Share
29.57 15.85 12.07 11.95 10.09 6.42 2.90 10.61 11.09 13.30
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
29.57 15.85 12.07 11.95 10.09 6.42 2.90 10.61 11.09 13.30
Free Cash Flow
8,972.00 3,760.00 792.00 5,731.40 6,056.10 5,111.70 3,802.70 4,313.90 4,538.80 3,887.40
Working Capital
20,401.00 4,364.00 (1,566.20) 896.30 3,399.70 4,980.50 1,934.40 8,661.50 4,666.20 4,114.80
Capital Expenditures
(7,841.00) (5,058.00) (3,448.00) (1,854.30) (1,309.80) (1,387.90) (1,033.90) (1,210.60) (1,076.80) (963.60)
Net Current Asset Value
(30,312.00) (31,703.00) (27,415.60) (20,679.90) (21,198.80) (23,345.80) (22,877.40) (12,449.70) (14,111.00) (9,624.00)
EV/EBIT
38.00 55.95 85.29 48.15 41.45 27.43 27.21 34.16 45.43 24.93
Capex to Sales
0.12 0.11 0.10 0.07 0.05 0.06 0.05 0.06 0.05 0.05
Price to Operating Income
36.66 53.90 82.56 46.18 39.41 25.30 24.60 33.65 44.47 24.21
Other line items
Depreciation/Fixed assets
0.08 0.10 0.12 0.15 0.17 0.15 0.16 0.20 0.18 0.18
Cash ROIC
12.02% 8.16% 2.47% 20.67% 21.32% 19.58% 18.48% 15.07% 13.61% 12.78%
Accounts Receivable Turnover
3.90 3.66 3.43 3.42 3.76 3.94 3.94 3.89 3.98 4.80
Accounts Payable Turnover
2.57 2.89 3.13 3.68 4.46 3.64 3.61 3.58 3.22 4.25
Inventory Turnover
1.04 1.26 1.40 1.62 1.86 1.53 1.50 1.24 1.11 1.63
Average Days of Payables
177.65 140.01 133.94 106.29 83.38 106.95 108.64 94.11 115.77 86.25
Days of Inventory on Hand
453.91 329.06 297.53 237.27 193.96 264.95 246.68 241.54 365.87 227.68
Average Receivables
16,715.50 12,306.10 9,947.55 8,343.05 7,528.10 6,235.25 5,659.15 5,519.50 5,014.25 4,418.95
Average Payables
4,304.00 2,913.90 2,264.70 1,800.60 1,638.65 1,506.00 1,306.20 1,308.90 1,380.00 1,343.75
Average Inventory
10,666.50 6,680.90 5,041.25 4,097.85 3,933.15 3,585.50 3,144.40 3,778.20 4,010.10 3,503.85
Average Assets
95,595.50 71,360.65 56,748.05 49,147.90 47,719.55 42,959.60 41,597.25 44,444.70 41,893.45 37,187.40
Average Common Equity
20,403.50 12,567.85 10,819.55 9,965.10 7,490.00 4,262.15 6,804.10 11,288.50 12,874.20 14,335.40

Fold the line items

Columns are period end dates